Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

By A. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. Deininger, Brian J. Druker. Journal of Clinical Investigation, 2011

799 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/05ddeb8ffe0adebe1087d2102b7cc8e74d9fc629

Citations in the corpus

• Proteolysis Targeting Chimeras as Therapeutics and Tools for Biological Discovery (2020, neutral): “A population of CML stem cells survives despite the inhibition of oncogenic kinase activity (Corbin et al., 2011), and it had been postulated they depend on kinase-independent roles of BCR-Abl for survival.”